The use of NovaSure for endometrial ablation results a variety of poor pregnancy outcomes, according to a study presented by Shannon Smith, MD, at the Global Congress of the American Association of Gynecologic Laparoscopists.
The use of NovaSure for endometrial ablation results a variety of poor pregnancy outcomes, according to a study presented by Shannon Smith, MD, at the Global Congress of the American Association of Gynecologic Laparoscopists.
In the study, “Pregnancy Outcomes following NovaSure Endometrial Ablation Procedure,” Smith said pregnancy after radiofrequency endometrial ablation is rare, and results in significant complications, morbidity and adverse outcomes for both the patient and fetus. The study aimed to determine whether contraceptive counseling was provided after ablation, and evaluate the outcomes of pregnancies that occurred following endometrial ablation using NovaSure.
The study included preliminary results for six of 20 patients who became pregnant following a NovaSure ablation procedure. Patents were from multiple centers around the United States.
A survey of physicians indicated that four pregnancies resulted in preterm birth between 27 and 36 weeks. One ended in spontaneous abortion in the first trimester; another was continuing into the third trimester without complications.
At conception, patients were between 26 and 29 years old; none reported using a reliable method of birth control. One patient received contraceptive counseling; three did not. One patient was unsure whether she’d been counseled to use contraception.
When pregnancy continued past the first trimester, a number of complications arose:
• Intrauterine growth restriction (IUGR) requiring cesarean hysterectomy,
• Preterm premature rupture of the membrane, placenta acretia, postpartum pyelonephritis with sepsis.
• Fetal distress/decelerations, terminal bradycardia
• IUGR, non-reassuring fetal heart tracing
Smith said, “These results emphasize the importance of physician counseling on the use of a reliable birth control method for patients undergoing endometrial ablation.”
Mail-order dispensing of mifepristone for medication abortion found effective
May 13th 2024A recent study revealed that mail-order pharmacy dispensing of mifepristone for medication abortion proves effective and satisfactory, highlighting a potential avenue for expanding access to reproductive healthcare.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More